Novo Nordisk Navigates Patent Expiry and Enhanced Drug Approval

Novo Nordisk gains FDA approval for potent Wegovy HD while facing generic competition in India after semaglutide patent expiry, shaping its 2026 outlook.

The Danish pharmaceutical giant Novo Nordisk finds itself navigating two significant, simultaneous developments that are shaping investor sentiment. Within a single day, the company faced the expiration of a crucial patent in a major market and received regulatory approval for an upgraded version of its blockbuster drug.

FDA Greenlights More Potent Wegovy Formulation

On March 19, 2026, the U.S. Food and Drug Administration (FDA) approved a higher-dose variant of the weight-loss medication Wegovy. Designated Wegovy HD, this new formulation contains 7.2 mg of semaglutid. Clinical data from the STEP UP trial demonstrated its superior efficacy: over a 72-week period, patients using the 7.2 mg dose achieved an average weight reduction of 20.7% of their body mass. This compares favorably to the 17.5% average loss associated with the current standard 2.4 mg dose. The company has scheduled the U.S. launch for April 2026.

Market analysts view this development as a strategic move to bolster the product portfolio. Wegovy HD is expected to help Novo Nordisk improve its product mix and defend its market position against emerging competitive therapies in the global obesity treatment sector.

Indian Market Braces for Generic Competition

Merely 24 hours after the FDA decision, on March 20, 2026, Novo Nordisk's exclusivity protection for semaglutid expired in India. This patent cliff has triggered preparations for a wave of affordable generic alternatives. Over 40 domestic pharmaceutical firms, including industry leaders Sun Pharma, Dr. Reddy's Laboratories, and Lupin, are poised to introduce their versions.

Substantial price erosion is already evident. Natco Pharma announced plans to offer a monthly semaglutid injection for approximately $14. Other manufacturers are targeting a price range of 3,000 to 5,000 Indian rupees per month—a fraction of the cost of the branded Ozempic and Wegovy products. In anticipation of this intensified competition, Novo Nordisk has proactively implemented price adjustments and formed a local partnership with Emcure Pharmaceuticals.

Cautious Outlook Amidst Market Pressure

Novo Nordisk shares have been trading near their 52-week low, reflecting sustained market pressure. The company's own guidance for 2026 anticipates a low single-digit negative impact on sales growth, measured at constant exchange rates. This forecast incorporates the mounting competitive challenges in emerging markets and broader pricing pressures worldwide for anti-obesity medications.

The dual events underscore the complex landscape for leading drugmakers: the constant need for innovation to stay ahead through enhanced products, juxtaposed with the inevitable loss of market exclusivity in key regions.